Market Research Report
Diagnostics and Therapeutics for HIV: Global Markets
|Published by||BCC Research||Product code||180820|
|Published||Content info||184 Pages
Delivery time: 1-2 business days
|Diagnostics and Therapeutics for HIV: Global Markets|
|Published: October 24, 2018||Content info: 184 Pages||
The global HIV therapeutics market should reach $27.1 billion by 2023 from $22.0 billion in 2018 at a compound annual growth rate (CAGR) of 4.3% for the period of 2018 to 2023.
The single-tablet regimen FDC drug market is expected to grow from $7.9 billion in 2018 to $10.1 billion in 2023 at a CAGR of 4.9% for the period of 2018 to 2023.
The nucleoside/nucleotide reverse transcriptase inhibitors drug market is expected to grow from $6.4 billion in 2018 to $7.9 billion in 2023 at a CAGR of 4.2% for the period of 2018 to 2023.
This report organizes information from diverse sources into sections, including an overview, industry structure, diagnostic test type, treatment by drug categories, leading drug profiles and historic drug sales, regulations, reimbursements and patents. The scope of this report includes an overview of the global market scenario for diagnosis and treatments of HIV, with base year data from 2017, estimations for 2018 and forecasts for 2023 using projections of CAGR during the forecast period. Market data in terms of value is provided at global, regional and country levels for treatments by drug categories. Market data for HIV diagnostics is provided for regional levels, with details on test types. Estimated values are based on companies' total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
The report forecasts the global market for HIV therapeutics by drug class and discusses market data for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), single tablet regimen fixed-dose combination (STR FDC), HIV integrase stand transfer inhibitors (INSTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). The enzyme inhibitor drug class has been excluded when calculating the global HIV therapeutics market, as there are no late-stage pipeline molecules.
Diagnostic tests such as antigen- and antibody-based tests, CD4 tests and viral load tests are detailed with current and forecasted market data. Antigen- and antibody-based tests cover enzyme-linked immunosorbent assay (ELISA) tests, enzyme immunoassay (EIA) tests, rapid tests and NAT tests; CD4 tests include tests conducted to monitor the CD4 load; and viral load tests include all PCR-based tests.
Market dynamics, such as trends and challenges, are discussed in the report. This report also involves regional market overviews for North America, Europe, Asia-Pacific and Rest of the World. The regional overviews provide information on the epidemiology of HIV by country and region and details market data for each region. The regulatory scenario is discussed for the United States, Europe and Japan to provide an overview of the regulations for new drug launches and diagnostic kits. The reimbursement scenario is outlined for the United States, Europe and Japan to provide an overview to readers of this report. The pipeline analysis chapter discusses four major drug categories to provide details on major pipeline developments. The competitive landscape discusses the major manufacturers involved in the HIV therapeutics market, key developments and product offerings.